LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 9 of 15: Cell count and normalized growth rate inhibition values within biological replicate 2. - Dataset (ID:20246)
Download: Excel (XLSX), Comma-separated (CSV)
Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Normalized Growth Rate Inhibition Value |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
BT-20 | Tozasertib | 0.37 | uM | LJP5 | 3 | B16 | 72 | hr | 1334 | 1136 | 4117 | 0.2759 | -0.0944 |
BT-20 | Tozasertib | 1.11 | uM | LJP5 | 1 | B15 | 72 | hr | 1334 | 1001 | 3930 | 0.2547 | -0.1686 |
BT-20 | Tozasertib | 1.11 | uM | LJP5 | 2 | B15 | 72 | hr | 1334 | 1030 | 4051 | 0.2543 | -0.1494 |
BT-20 | Tozasertib | 1.11 | uM | LJP5 | 3 | B15 | 72 | hr | 1334 | 978 | 4117 | 0.2375 | -0.1741 |
BT-20 | Tozasertib | 3.33 | uM | LJP5 | 1 | B14 | 72 | hr | 1334 | 1040 | 3930 | 0.2646 | -0.1479 |
BT-20 | Tozasertib | 3.33 | uM | LJP5 | 2 | B14 | 72 | hr | 1334 | 1024 | 4051 | 0.2528 | -0.1525 |
BT-20 | Tozasertib | 3.33 | uM | LJP5 | 3 | B14 | 72 | hr | 1334 | 1011 | 4117 | 0.2455 | -0.1571 |
BT-20 | Tozasertib | 10 | uM | LJP5 | 1 | B13 | 72 | hr | 1334 | 1068 | 3930 | 0.2717 | -0.1333 |
BT-20 | Tozasertib | 10 | uM | LJP5 | 2 | B13 | 72 | hr | 1334 | 1017 | 4051 | 0.2510 | -0.1561 |
BT-20 | Tozasertib | 10 | uM | LJP5 | 3 | B13 | 72 | hr | 1334 | 1061 | 4117 | 0.2577 | -0.1317 |
BT-20 | Imatinib | 0.04 | uM | LJP6 | 1 | N18 | 72 | hr | 1334 | 3352 | 3955 | 0.8474 | 0.7995 |
BT-20 | Imatinib | 0.04 | uM | LJP6 | 2 | N18 | 72 | hr | 1334 | 3825 | 3899 | 0.9810 | 0.9753 |
BT-20 | Imatinib | 0.04 | uM | LJP6 | 3 | N18 | 72 | hr | 1334 | 4315 | 3921 | 1.1004 | 1.1269 |
BT-20 | Imatinib | 0.12 | uM | LJP6 | 1 | N17 | 72 | hr | 1334 | 3253 | 3955 | 0.8223 | 0.7654 |
BT-20 | Imatinib | 0.12 | uM | LJP6 | 2 | N17 | 72 | hr | 1334 | 3991 | 3899 | 1.0236 | 1.0303 |
BT-20 | Imatinib | 0.12 | uM | LJP6 | 3 | N17 | 72 | hr | 1334 | 3938 | 3921 | 1.0042 | 1.0055 |
BT-20 | Imatinib | 0.37 | uM | LJP6 | 1 | N16 | 72 | hr | 1334 | 3501 | 3955 | 0.8850 | 0.8501 |
BT-20 | Imatinib | 0.37 | uM | LJP6 | 2 | N16 | 72 | hr | 1334 | 3917 | 3899 | 1.0046 | 1.0059 |
BT-20 | Imatinib | 0.37 | uM | LJP6 | 3 | N16 | 72 | hr | 1334 | 3977 | 3921 | 1.0142 | 1.0182 |
BT-20 | Imatinib | 1.11 | uM | LJP6 | 1 | N15 | 72 | hr | 1334 | 3343 | 3955 | 0.8451 | 0.7964 |
BT-20 | Imatinib | 1.11 | uM | LJP6 | 2 | N15 | 72 | hr | 1334 | 4220 | 3899 | 1.0823 | 1.1049 |
BT-20 | Imatinib | 1.11 | uM | LJP6 | 3 | N15 | 72 | hr | 1334 | 4043 | 3921 | 1.0310 | 1.0397 |
BT-20 | Imatinib | 3.33 | uM | LJP6 | 1 | N14 | 72 | hr | 1334 | 3895 | 3955 | 0.9846 | 0.9803 |
BT-20 | Imatinib | 3.33 | uM | LJP6 | 2 | N14 | 72 | hr | 1334 | 3985 | 3899 | 1.0220 | 1.0284 |
BT-20 | Imatinib | 3.33 | uM | LJP6 | 3 | N14 | 72 | hr | 1334 | 3900 | 3921 | 0.9946 | 0.9930 |